Abstract
Technetium-99m tetrofosmin (Myoview) has unique properties for myocardial perfusion imaging very early after injection of the tracer. We used a very short same-day rest/stress protocol, to be performed within 2 h and evaluated its diagnostic accuracy. The study included 144 patients from seven Spanish and four Portuguese centres with a diagnosis of uncomplicated coronary artery disease (CAD); 78 patients (54%) had no history of prior myocardial infarction. Patients were injected with ≤300 MBq99mTc-tetrofosmin at rest and ≤900 MBq approximately 1 h later at peak exercise. Single-photon emission tomographic (SPET) acquisitions were initiated within 5–30 min post injection. The results were compared with those of coronary angiography (CA). The data of 142 patients were completely evaluable (two with non-evaluable images were excluded). The quality of rest images was excellent or good in 86%, regionally problematic in 7%, poor but well interpretable in 5% and non-evaluable in 2%. The overall sensitivity for the detection of CAD was 93%, the specificity 38% and the accuracy 85%. The localization of defects by SPET in relation to the perfusion territories of stenosed vessels (≽50%) was achieved with a sensitivity of 64% for the left anterior descending artery, 49% for the left circumflex artery and 86% for the right coronary artery, and an accuracy of 71%, 72% and 73% respectively. Concordance of SPET and CA was 62% for single-vessel disease and 68% for multivessel disease. In conclusion, this Spanish-Portuguese multicentre clinical trial confirmed, in a considerable number of patients who underwent coronary angiography, the feasibility of99mTc tetrofosmin (Myoview) rest/stress myocardial SPET using a very short protocol (2 h).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DePuey EG. An update on radiopharmaceuticals for myocardial perfusion imaging.J Nucl Med 1994; 35: 17N-20N.
Sinusas AJ, Shi Q, Saltzberg MT, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia.J Nucl Med 1994;35:664–671.
Sridhara BS, Braat S, Rigo P, et al. Comparison of myocardial perfusion imaging with technetium-99m-tetrofosmin versus thallium-201 in coronary artery disease.Am J Cardiol 1993; 72:1015–1019.
Sridhara B, Sochor H, Rigo P, et al. Myocardial single-photon emission computed tomographic imaging with technetium99m-tetrofosmin: stress-rest imaging with same-day and separate-day rest imaging.J Nucl Cardiol 1994; 1: 138–143.
Berman DS, Kiat HS, Van Train KF, Germano G, Maddahi J, Friedman JD. Myocardial perfusion imaging with technetium99m-sestamibi: comparative analysis of available imaging protocols.J Nucl Med 1994; 35: 681–688.
Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med 1993; 34: 222–227.
Jain D, Wackers FIT, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium-99m-tetrofosmins: myocardial perfusion imaging agent: implications for a one-day imaging protocol.J Nucl Med 1993; 34: 1254–1259.
Nakajima K, Taki J, Shuke N, Bunko H, Takata S, Hisada K. Myocardial perfusion imaging and dynamic analysis with technetium-99m tetrofosmin.J Nucl Med 1993; 34: 1478–1484.
Wackers F, Berman D, Maddahi J, et al. Technetium-99m hexakis-2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging.J Nucl Med 1989; 30: 301–311.
Rigo P, Leclercq B, Itti R, Lahiri A, Braat S. Technetium99m-tetrofosmin myocardial imaging: a comparison with thallium-201 and angiography.J Nucl Med 1994; 35: 587–593.
Zaret BL, Rigo P, Wackers FIT, et al. and the Tetrofosmin International Trial Study Group. Myocardial perfusion imaging with technetium-99m tetrofosmin. Comparison with T1-201 imaging and coronary angiography in a phase III multicenter trial.Circulation 1995; 91: 313–319.
Sasaki Y, Nishimura T, Kubo A, et al. Evaluation of the clinical usefulness of a new myocardial imaging agent technetium-99m tetrofosmin PPN1011. A report of multicenter phase III clinical trials.Jpn J Nucl Med 1993; 30: 257–271.
Tamaki N, Takahashi N, Kawamoto M, et al. Myocardial tomography using technetium-99m-tetrofosmin to evaluate coronary artery disease.J Nucl Med 1994; 35: 594–600.
Braat SH, Leclerq B, Itti R, Lahiri A, Sridhara B, Rigo P. Myocardial imaging with technetium-99m-tetrofosmin: comparison of one-day and two-day protocols.J Nucl Med 1994; 35:1581–1585.
Highley B, Smith FW, Smith T, et al. Technetium-99m-1,2bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34: 30–38.
Jurado López JA, Ruiz Salmerón R, Díaz Buschmann I, et al. Aplicación de la actividad media contenida en regiones de interés circulares del mapa polar en la identificación de arterias coronarias lesionadas.Rev Esp Cardiol 1995; 48: 164–175.
Van Train KF, Garcia EV, Maddahi J, et al. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms.J Nucl Med 1994; 35: 609–618.
Author information
Authors and Affiliations
Additional information
The results contained herein were presented in part at the 2nd International Conference of Nuclear Cardiology, held in Cannes, France, on 23–26 April 1995
Rights and permissions
About this article
Cite this article
Montz, R., Perez-Castejón, M.J., Jurado, J.A. et al. Technetium-99m tetrofosmin rest/stress myocardial SPET with a same-day 2-hour protocol: comparison with coronary angiography A Spanish-Portuguese multicentre clinical trial. Eur J Nucl Med 23, 639–647 (1996). https://doi.org/10.1007/BF00834525
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00834525